Daniela Bertinetti

Daniela Bertinetti

Auto-generated profile, based on publicly available information

Daniela Bertinetti

Institute for Biology, Department of Biochemistry, University of Kassel, Kassel, Germany

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 December 2013 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
KMKathrin Muda
Kathrin Muda
DBDaniela Bertinetti
Daniela Bertinetti
FGFrank Gesellchen
Frank Gesellchen
JHJennifer Sarah Hermann
Jennifer Sarah Hermann
FZFelix von Zweydorf
Felix von Zweydorf
FHFriedrich W. Herberg
Friedrich W. Herberg
Significance: Leucine-rich repeat kinase 2 (LRRK2) is a multidomain protein implicated in Parkinson disease, and cAMP-dependent protein kinase (PKA) has been suggested to act as an upstream kinase phosphorylating LRRK2. Using a phosphoproteomics approach, we identified several novel PKA phosphorylation sites on LRRK2. We could demonstrate that one PKA phosphosite comprises the second most common mutation in LRRK2 (R1441C/G/H) attributed to Parkinson disease. Our findings reveal that this site is mandatory for subsequent 14-3-3 binding and affects LRRK2 kinase activity. These data provide a mechanistic insight into the regulation of LRRK2 kinase activity and its perturbation by disease-associated mutations.

1 December 2011 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
MLMarco Lolicato
Marco Lolicato
MNMarco Nardini
Marco Nardini
SGSabrina Gazzarrini
Sabrina Gazzarrini
SMStefan Möller
Stefan Möller
DBDaniela Bertinetti
Daniela Bertinetti
AMAnna Moroni
Anna Moroni
Hyperpolarization-activated cyclic nucleotide-gated (HCN) channels are dually activated by hyperpolarization and binding of cAMP to their cyclic nucleotide binding domain (CNBD). HCN isoforms respond differently to cAMP; binding of cAMP shifts activation of HCN2 and HCN4 by 17 mV but shifts that of HCN1 by only 2–4 mV. To explain the peculiarity of HCN1, we solved the crystal structures and performed a biochemical-biophysical characterization of the C-terminal domain (C-linker plus CNBD) of the three isoforms. Our main finding is that tetramerization of the C-terminal domain of HCN1 occurs at basal cAMP concentrations, whereas those of HCN2 and HCN4 require cAMP saturating levels. Therefore, HCN1 responds less markedly than HCN2 and HCN4 to cAMP increase because its CNBD is already partly tetrameric. This is confirmed by voltage clamp experiments showing that the right-shifted position of V½ in HCN1 is correlated with its propensity to tetramerize in vitro. These data underscore that ligand-induced CNBD tetramerization removes tonic inhibition from the pore of HCN channels.

20 January 2015 in PLOS Biology
Verified
Journal Article
Open access
PDF file
FSFrank Schwede
Frank Schwede
DBDaniela Bertinetti
Daniela Bertinetti
CLCarianne N. Langerijs
Carianne N. Langerijs
MHMichael A. Hadders
Michael A. Hadders
HWHans Wienk
Hans Wienk
HRHolger Rehmann
Holger Rehmann
The second messenger cAMP is known to augment glucose-induced insulin secretion. However, its downstream targets in pancreatic β-cells have not been unequivocally determined. Therefore, we designed cAMP analogues by a structure-guided approach that act as Epac2-selective agonists both in vitro and in vivo. These analogues activate Epac2 about two orders of magnitude more potently than cAMP. The high potency arises from increased affinity as well as increased maximal activation. Crystallographic studies demonstrate that this is due to unique interactions. At least one of the Epac2-specific agonists, Sp-8-BnT-cAMPS (S-220), enhances glucose-induced insulin secretion in human pancreatic cells. Selective targeting of Epac2 is thus proven possible and may be an option in diabetes treatment. cAMP is a small molecule produced by cells that activates proteins involved in a wide range of biological processes, including olfaction, pacemaker activity, regulation of gene expression, insulin secretion, and many others. In the case of insulin secretion, cAMP seems to impinge on different stages of the signalling cascade to regulate secretory activity in pancreatic β-cells. Here we have developed a chemically modified version of cAMP that specifically only activates Epac2, one of the cAMP-responsive proteins in this cascade. Furthermore, our cAMP analogue activates Epac2 more potently than cAMP itself does. We have determined several crystal structures of Epac2 in complex with cAMP analogues to help us explain the molecular basis of the observed selectivity and the strong activation potential. In addition, we were able to show that the analogue is able to potentiate glucose-induced secretion of insulin from human pancreatic islets. The principal challenge during this study was identifying and understanding small differences in the cAMP-binding domains of cAMP-regulated proteins and matching these differences with suitable modifications of the cAMP molecule.

22 July 2015 in ACS Chemical Biology
Verified
Journal Article
Closed access
MKMatthias J. Knape
Matthias J. Knape
LALalima G. Ahuja
Lalima G. Ahuja
DBDaniela Bertinetti
Daniela Bertinetti
NBNicole C.G. Burghardt
Nicole C.G. Burghardt
BZBastian Zimmermann
Bastian Zimmermann
FHFriedrich W. Herberg
Friedrich W. Herberg

6 October 2022 in Nature Structural & Molecular Biology
Verified
Journal Article
Closed access
PDF file
JHJohn T. Happ
John T. Happ
CACorvin D. Arveseth
Corvin D. Arveseth
JBJessica Bruystens
Jessica Bruystens
DBDaniela Bertinetti
Daniela Bertinetti
INIsaac B. Nelson
Isaac B. Nelson
BMBenjamin R. Myers
Benjamin R. Myers

14 January 2014 in ACS Chemical Biology
Verified
Journal Article
Open access
YWYuxiao Wang
Yuxiao Wang
THTienhuei G. Ho
Tienhuei G. Ho
DBDaniela Bertinetti
Daniela Bertinetti
MNMatthias Neddermann
Matthias Neddermann
EFEugen Franz
Eugen Franz
EKEileen J. Kennedy
Eileen J. Kennedy
A-kinase anchoring proteins (AKAPs) play an important role in the spatial and temporal regulation of protein kinase A (PKA) by scaffolding critical intracellular signaling complexes. Here we report the design of conformationally constrained peptides that disrupt interactions between PKA and AKAPs in an isoform-selective manner. Peptides derived from the A Kinase Binding (AKB) domain of several AKAPs were chemically modified to contain an all-hydrocarbon staple and target the docking/dimerization domain of PKA-R, thereby occluding AKAP interactions. The peptides are cell-permeable against diverse human cell lines, are highly isoform-selective for PKA-RII, and can effectively inhibit interactions between AKAPs and PKA-RII in intact cells. These peptides can be applied as useful reagents in cell-based studies to selectively disrupt AKAP-localized PKA-RII activity and block AKAP signaling complexes. In summary, the novel hydrocarbon-stapled peptides developed in this study represent a new class of AKAP disruptors to study compartmentalized RII-regulated PKA signaling in cells.